Cationic/Ionizable Lipids

As one of the major supplier in market, DC Chemicals provide more than 500 novel cationic ionizable lipids with wide range of diverse chemical structures for RNA delivery.

Cationic ionizable lipids play a major role in the LNP formulation and its ability to transfect target cells with its cargo. The ionizable lipids are used to complex negatively charged nucleic acid cargo. The mRNA-cationic lipid complex fuses with the cell membrane and is then delivered into the cytosol. To be able to play these roles efficiently, a cationic ionizable lipid must be engineered with a suitable apparent acid dissociation constant (pKa). The apparent pKa of a cationic ionizable lipid is the likely pKa at the LNP surface. Currently, the cationic ionizable lipids in FDA-approved therapeutics all have an apparent pKa between 6-7. This is crucial for the cationic ionizable lipid to maintain a neutral charge while in systemic circulation (pH above the pKa of the lipid, pH ~7.5), as well as its ability to become positively charged in the endosome (pH ~6.5) and facilitate membrane fusion and subsequent cytosolic release.

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC66524	BP Lipid 323	BP Lipid 323 is an ionizable aminolipid analog of CL1 which features a unique azetidine head and an ester linking to a polyunsaturated hydrophobic tail. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.
DC66525	BP Lipid 321	BP Lipid 321 is an ionizable aminolipid analog of CL1 which features a unique 3-hydroxyazetidine head and an ester linking to a polyunsaturated hydrophobic tail. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.
DC66526	BP Lipid 322	BP Lipid 322 is a multichargeable lipid analog of CL1 which features a novel 2-hydroxyethyl piperazine ionizable head and an ester linking to a polyunsaturated hydrophobic tail. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.
DC60619	12T-O14	12T-O14 is a amidine-incorporated degradable (AID) lipid for versatile mRNA delivery. 12T-O14-LNPs mediate efficient intramuscular delivery of mRNA vaccines and systemic delivery of mRNA therapeutics without noticeable toxicity. 12T-O14 serves as a superior supplementary lipid to redirect liver-tropic LNPs to selectively target the lung or spleen via simple adjustment of the formulation.
DC60636	Acid-degradable Cationic Lipid (ADC) Featured	Acid-degradable Cationic Lipid (ADC) composed of cationic lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo.
DC60639	Acid-degradable Anionic Lipid (ADA) Featured	Acid-degradable Anionic Lipid (ADA) composed of anionic lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo.
DC66648	CP-LC-1143 Featured	Lipid CP-LC-1143 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity.
DC66649	CP-LC-1254	Lipid CP-LC-1254 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity.
DC66650	CP-LC-0729	CP-LC-0729 is an ionizable lipid that significantly surpasses the MC3 in protein expression while showing no in vivo toxicity. CP-LC-0729 demonstrates a very high selectivity to lungs with a remarkable 32-fold increase in protein expression compared to MC3.
DC66652	CP-LC-0867	Lipid CP-LC-0867 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity.
DC66653	C9-200	C9-200 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNPs).1 LNPs containing C9-200 and encapsulating mRNA encoding erythropoietin (EPO) increase serum EPO levels in mice. LNPs containing C9-200 and encapsulating mRNA encoding the Cas9 nuclease and small-guide RNA (sgRNA) targeting transthyretin (TTR) induce 3-fold higher hepatic insertion and deletion (indel) formation than LNPs containing C12-200 (Item No. 36699) and encapsulating mRNA encoding Cas9 in mice.
DC66654	Lipid N2-3L	Lipid N2-3L is an ionizable cationic lipid (pKa = 8.99) that has been used in the generation of supramolecular lipid nanoparticles (SMLNPs) encapsulating mRNA for use in vitro and in vivo.1 SMLNPs containing lipid N2-3L and encapsulating a luciferase reporter accumulate at the site of injection and in the draining lymph nodes of mice. Lipid N2-3L-containing SMLNPs encapsulating ovalbumin mRNA and the toll-like receptor 7/8 (TLR7/8) agonist R-848 (Item No. 14806) as an adjuvant promote dendritic cell maturation and antigen presentation, reduce tumor volume, and increase survival in an MC-38-OVA murine model of colon cancer.
DC66655	YHS-12	YHS-12 is an ionizable cationic lipid (pKa = 6.506) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of siRNA and mRNA in vitro and in vivo.1 LNPs containing YHS-12 and the macrophage targeting peptide CRVLRSGSC and encapsulating mRNA encoding chimeric antigen receptor targeting methicillin-resistant S. aureus (MRSA) and siRNA targeting caspase-11 increase the phagocytosis rate of MRSA in RAW 264.7 macrophages and primary mouse bone marrow-derived macrophages (BMDMs). Intravenous administration of these LNPs decreases blood bacterial burden and increases survival in a model of sepsis using cyclophosphamide-induced immunosuppressed mice.
DC60662	Si6-C14b	Si6-C14b is a siloxane-incorporated lipid for livertargeting mRNA delivery. The siloxane moieties enhance cellular internalization of mRNA-LNPs and improve their endosomal escape capacity, augmenting their mRNA delivery efficacy.
DC60663	Si5-N14 Featured	Si5-N14 is a siloxane-incorporated lipid for lung-targeting mRNA delivery. The siloxane moieties enhance cellular internalization of mRNA-LNPs and improve their endosomal escape capacity, augmenting their mRNA delivery efficacy.
DC60664	Si12-C10	Si12-C10 is a siloxane-incorporated lipid for spleen-targeting mRNA delivery. The siloxane moieties enhance cellular internalization of mRNA-LNPs and improve their endosomal escape capacity, augmenting their mRNA delivery efficacy.
DC60670	CL4F11-ζ-2	CL4F11_ζ-2 is an ionizable lipid for hepatic delivery of CRISPR/Cas ribonucleoprotein (RNP). CL4F11_ζ-2 LNP shows an extremely strong inhibitory effect of serum TTR protein levels compared with all the approved ionizable lipids including DLin-MC3-DMA (MC3), SM-102, and ALC-0315.
DC60673	(+)CP-LC-0729	(+)CP-LC-0729 is an cationic lipid derived from CP-LC-0729 and achieves significantly higher expression and selectivity highlights the advantages of this lipid system for lung-targeted delivery.
DC60683	Lipid-168	Lipid-168 is a lipid for mRNA delivery. LNP-168 can efficiently deliver functional mRNA to HSPCs in vivo.
DC60684	Lipid I97	Lipid I97 is a vitamin B5-derived ionizable lipid for mRNA vaccine delivery. Lipid I97 LNP specifically delivers the mRNA to the spleen and lymph nodes in model mice, induces balanced Th1/Th2 immune responses, and elicits the production of high levels of neutralizing antibodies with low toxicity.
DC60685	313O13	313O13 is an ionizable lipid with amine headgroups which drives LNP immunogenicity by binding to Toll-like receptor 4 and CD1d and by promoting lipid-raft formation. 313O13 prevents the often-observed loss of efcacy in the LNP-mediated delivery of siRNA and mRNA.
DC60686	313oi10	313oi10 is an ionizable lipid with amine headgroups which drives LNP immunogenicity by binding to Toll-like receptor 4 and CD1d and by promoting lipid-raft formation. 313oi10 prevents the often-observed loss of efcacy in the LNP-mediated delivery of siRNA and mRNA.
DC99010	Lipid A-11 (compound A-11)	Compound A-11 (Lipid A11) is a novel ionizable cationic lipid for used for tLNP(targeting antibody LNP) targeting to T cell,with pKa range 6-7, high encapsulation efficiency and high T cell transfection, compared to benchmark ATX-126 and other lipids.
DC67116	80-O14B	80-O14B is an cationic lipid-like compound for CRISPR/Cas9 delivery.
DC67117	113-N16B Featured	113-N16B is an ionizable cationic lipid used for the generation of lipid nanoparticles (LNPs). 113-N16B delivers mRNA preferentially to pulmonary endothelial cells.
DC67118	PNI 132	PNI 132, an ionizable lipid derived from the patent WO2020252589A, is useful in the formulation of lipid nanoparticles.
DC67120	YSK 12C4	YSK 12C4 is an ionizable cationic lipid primarily used to enhance siRNA cellular delivery via multifunctional envelope-type nanodevices (MEND). YSK 12C4 promotes siRNA uptake and endosomal escape, effectively silencing genes in human immune cell lines.
DC67121	1-A-N	1-A-N is a lipid nanoparticle (LNP) used for in vivo delivery of siRNA. 1-A-N can regulate immune response by delivering siCD45 (siRNA targeting CD45) to T cells and silencing the CD45 gene.
DC67122	Lipid 50	Lipid 50 (compound 50) is an ionizable lipid that can be used for the generation of lipid nanoparticles (LNPs). Lipid 50 is a carrier for both siRNA and mRNA.
DC67125	Ionizable lipid Az1	Ionizable lipid Az1is an ionizable lipid which can react with a variety of terminal alkynes under the CuAAC standard condition.

<Prev1...6 7 8 9 10 11 Next>

Cationic/Ionizable Lipids

Customized Consultation X

Your information is safe with us. * Required Fields.